14 Nov Intentional Self-Harm with GLP-1 Receptor Agonists for Diabetes
Posted at 10:28h
in
Intentional Self-Harm with GLP-1 Receptor Agonists for Diabetes
OS0009_CDM
Overview
Background
- Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of drugs indicated for the treatment of type 2 diabetes. Certain GLP-1 receptor agonists (liraglutide and semaglutide) are also indicated for cardio protection for type 2 diabetes and chronic weight management for obesity; however, these agents are likely being used off-label for weight loss in persons without diabetes or obesity.
- Recently, safety concerns with their use have been raised, including potential association with suicidal ideation and self-harm.
Objectives
- This study will replicate the FDA Sentinel study using the CNODES’ adaptation of the Sentinel Common Data Model with Canadian data to determine whether there is an increased risk of intentional self-harm among adult patients with diabetes who are newly treated with GLP-1 receptor agonists compared to those who are newly treated with sodium glucose cotransporter-2 (SGLT-2) inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors.